Optimization and screening of solid lipid nanoparticle production for gene delivery by factorial design and response surface methodology

Keywords: Solid lipid nanoparticle, factorial design, response surface method, gene delivery

Abstract

Aim: A successful gene therapy requires a delivery system for overcoming various biological barriers. For this, we adapted the factorial design and response surface methodology to the cationic solid lipid nanoparticle production process.

Methods: Screening and optimization of formulations were carried out with factorial design with 3 factors and 3 levels using Box-Behnken Design. Then, solid lipid nanoparticles were physicochemically characterized. Furthermore, optimal SLN formulation is examined in terms of complex formation with plasmid DNA, its protection potential against nucleases, cytotoxicity profile, and storage stability.

Results: Response-surface analyses demonstrated that the selected quadratic model holds significance for particle size and zeta potential. The interaction of independent variables was statistically determined. Optimization and prediction were performed using obtained second-order polynomial equations. Optimal formulation and complexes were found to be nanosized, positively charged and their polydispersity-index values below 0.3 as an indicator of being monodispersed.  Cytotoxicity of the optimal formulation is compatible for further studies and no significant increase was observed in particle size until day 21 and until day 60 for polydispersity-index.

Conclusion: Optimal formulation provides a good basis as a gene delivery system was produced with developed systematic. Briefly, this methodology could be used to obtain SLNs with desired conditions.

Published
2020-12-28
How to Cite
Akbaba, H., & Ozder, M. (2020, December 28). Optimization and screening of solid lipid nanoparticle production for gene delivery by factorial design and response surface methodology. EXPERIMENTAL BIOMEDICAL RESEARCH, 4(1), 23-37. https://doi.org/https://doi.org/10.30714/j-ebr.2021165779